Letairis Uptake “Excellent” In First Full Quarter, Gilead Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the PAH drug, which competes with Actelion’s Tracleer, were around $6 million, but free-month offer is about to end.
You may also be interested in...
Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis
Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.
Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis
Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.
Actelion Launches 500-Patient Phase III Trial For Next-Generation PAH Drug
Taking the Actelion-1 compound to market would give Swiss firm an edge in PAH battle with Gilead.